5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion
primidone methanol solution
CAS: 125-33-7
Molecular Formula: C12H14N2O2
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Names and Identifiers
| Name | primidone methanol solution |
| Synonyms | Primidone 2-deoxyphenobarbital 2-DESOXYPHENOBARBITAL primidone methanol solution 5-ethyl-5-phenylperhydropyrimidine-4,6-dione 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione 5-Ethylhexahydro-4,6-dioxo-5-phenylpyrimidine 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion 5-ethylhexahydro-4,6-dioxo-5-phenylphrimidine 5-Ethyl-5-phenyldihydro-4,6(1H,5H)-pyrimidinedione 5-ethyl-5-phenyldihydropyrimidine-4,6(1H,5H)-dione 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl- |
| CAS | 125-33-7 |
| EINECS | 204-737-0 |
| InChI | InChI=1/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16) |
| InChIKey | DQMZLTXERSFNPB-UHFFFAOYSA-N |
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Physico-chemical Properties
| Molecular Formula | C12H14N2O2 |
| Molar Mass | 218.25 |
| Density | 1.1402 (rough estimate) |
| Melting Point | 281-282°C |
| Boling Point | 358.94°C (rough estimate) |
| Flash Point | 9℃ |
| Solubility | Very slightly soluble in water, slightly soluble in ethanol (96 per cent). It dissolves in alkaline solutions. |
| Vapor Presure | 6.08E-11mmHg at 25°C |
| Appearance | Odor-free white crystalline powder with slightly bitter taste and no acidity |
| Color | White to Off-White |
| Merck | 14,7746 |
| pKa | 12.26±0.40(Predicted) |
| Storage Condition | Sealed in dry,Room Temperature |
| Refractive Index | 1.6660 (estimate) |
| Physical and Chemical Properties | Melting point 281-282°C water-soluble <0.1g/100 mL at 19°C |
| Use | For the treatment of grand mal epilepsy and psychomotor seizures |
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Risk and Safety
| Risk Codes | R22 - Harmful if swallowed R40 - Limited evidence of a carcinogenic effect R39/23/24/25 - R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. R11 - Highly Flammable |
| Safety Description | S22 - Do not breathe dust. S36 - Wear suitable protective clothing. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37 - Wear suitable protective clothing and gloves. S16 - Keep away from sources of ignition. S7 - Keep container tightly closed. |
| UN IDs | 3249 |
| WGK Germany | 3 |
| RTECS | UV9100000 |
| HS Code | 29335990 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Standard
Authoritative Data Verified Data
This product is 5-ethyl-5-phenyl-dihydro-4, 6 (1H,5h) pyrimidinedione. Calculated as dry product, containing C12H14N202 shall not be less than 98.5%.
Last Update：2024-01-02 23:10:35
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Trait
Authoritative Data Verified Data
- This product is white crystalline powder; Odorless.
- This product is slightly soluble in ethanol, and almost insoluble in water or acetone.
melting point
The melting point of this product (General 0612) is 280~284°C.
Last Update：2022-01-01 11:36:47
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Differential diagnosis
Authoritative Data Verified Data
- take 0.lg of this product, add 5ml chromotropic acid test solution, put it on a water bath and heat it for 30 minutes, which should be purple.
- take 0.lg of this product, add anhydrous sodium carbonate 0.lg mixed, heat burning, that is, there is ammonia, can make the wet red litmus test paper into blue.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 62).
Last Update：2022-01-01 11:36:47
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Exam
Authoritative Data Verified Data
clarity and color of dimethylformamide solution
take this product 0.l0g, add dimethylformamide 10ml after dissolution, the solution should be clear colorless.
chloride
take this product l. Add 50ml of water, shake for 5 minutes, filter, take 25ml of filtrate, and check according to law (General rule 0801). Compared with the control solution made of 7.0ml of standard gasification sodium solution, it should not be more concentrated (0.014%).
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
take 2.0g of this product and check it according to law (General rule 0841). The remaining residue shall not exceed 0.1%.
Heavy metals
take the residue left under the ignition residue item, add 1ml of nitric acid, and evaporate to dryness until the nitrogen oxide vapor is removed. Add 2ml of hydrochloric acid, dry on a water bath, and then add 5ml of water to evaporate to dryness, add 15ml of water and 4ml of acetate buffer (pH 3.5), slightly warm to dissolve, add water to make 50ml, shake; Take 25ml, check according to law (General rule 082) first method), heavy metals should not be more than 10 parts per million.
zinc salt
take the remaining solution under the above heavy metal item 25ml, put it in a 50ml Cuvette, add hydrochloric acid solution (1-2)4M l and potassium ferrocyanide solution 3ml, add water to the scale, shake well, in case of turbidity, take 44mg of zinc sulfate (ZnS04 • 7H20) with standard zinc solution, put it in a 100ml measuring flask, add water to dissolve and dilute to the scale, shake well, take 10ml with precision, in another 100ml measuring flask, dilute to the scale with water and shake to obtain. Each 1 ml is equivalent to 10ug of Zn]2ml of the control solution prepared by the same method should not be more concentrated (0.002%).
Last Update：2022-01-01 11:36:48
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Content determination
Authoritative Data Verified Data
take this product about 0.2g, precision weighing, according to the nitrogen determination method (General 0704 first method) determination. Each 1 ml of sulfuric acid titration solution (0.05mol/L) corresponds to 10.91mg of C12H14N202.
Last Update：2022-01-01 11:36:49
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Category
Authoritative Data Verified Data
antiepileptic drugs.
Last Update：2022-01-01 11:36:49
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 11:36:49
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Primidone
Authoritative Data Verified Data
This product contains 95.0% to 105.0% of the labeled amount of primidone (C12H14N202).
trait
This product is white tablet.
identification
take an appropriate amount of fine powder of this product (equivalent to 0.25g of primidone), Add 30ml of ethanol, dissolve the primidone at a slight temperature, and filter it. The filtrate was evaporated to dryness on a water bath, and the residue exhibited the same reaction according to the tests of the identification items (1) and (2) under the item of phenominone.
examination
- the dissolution of this product, according to the dissolution and release determination method (General rule 0931 second method), water 900ml as the dissolution medium, the speed of 50 rpm, according to the law, after 60 minutes, take the solution of lOtnl, filter, take the filtrate as the test solution; Another precision weighing of primidone control about 5mg(50mg specifications) or 10mg(lOOmg specifications) or 25mg(250mg specification), put in 100ml measuring flask, add appropriate amount of water, ultrasonic to dissolve, let cool, dilute to the scale with water, as a reference solution. The absorbance of the above two Solutions was measured at a wavelength of 0401 nm by ultraviolet-visible spectrophotometry (general), and the elution amount of each tablet was calculated. The limit is 70% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
- was measured by gas chromatography (General 0521).
- chromatographic conditions and system suitability test silicone (or similar polarity) was used as the stationary phase; Coating concentration was 3%; Column temperature was 260°C. The resolution between the peak of primidone and the peak of internal standard substance shall meet the requirements.
- correction factor measurement an appropriate amount of N-phenylcarbazole was taken, and methanol was added to dissolve and prepare a solution containing 2.4mg per 1 ml as an internal standard solution. Take about 0.15g of the reference product of primidone, weigh it precisely, put it in a 50ml measuring flask, add 25ml of internal standard solution precisely, shake to dissolve the primidone (heat to dissolve it if necessary), dilute to the scale with methanol, shake, as a control solution. Precision take the reference solution 1u1 injection gas chromatograph, calculate the correction factor.
- determination Method: Take 20 tablets of this product, precise weighing, fine grinding, precise weighing to take an appropriate amount of fine powder (equivalent to 0.15g of primidone), and put it in a 50ml measuring flask, precision Add internal standard solution 25ml and methanol 10ml, water bath heating for 5 minutes, and constantly shake, cool, dilute to the scale with methanol, shake, filter, precision quantity of filtrate 1u1 injection gas chromatograph, according to the internal standard method to calculate the peak area, that is obtained.
category
Same as primidone.
specification
(l)50mg (2)l00mg (3)250mg
storage
light shielding, sealed storage.
Last Update：2022-01-01 11:36:50
5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion - Reference Information
| NIST chemical information | Information provided by: webbook.nist.gov (external link) |
| (IARC) carcinogen classification | 2B (Vol. 108) 2016 |
| EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
| antiepileptic drugs | primidone belongs to barbiturate antiepileptic drugs, its antiepileptic effect is similar to phenobarbital, and it is effective for grand epileptic seizures and psychomotor seizures. It is converted into phenobarbital and phenylethylmalonamide with anticonvulsant effect in vivo, both of which have antiepileptic effect, and their effect is not as good as phenytoin sodium, but it can be combined with phenytoin sodium to enhance its effect. It is better than phenobarbital in controlling tonic and clonic epilepsy. |
| pharmacological action | the main metabolite of this product in vivo is phenobarbital, which works together with it. In vitro electrophysiological experiments can see the effect of opening chloride channels of nerve cells, depolarization of cells, and γ-aminobutyric acid (GABA). At the treatment concentration, it can reduce the excitatory effect of glutamate, strengthen the inhibitory effect of γ-aminobutyric acid, inhibit the single synaptic and multi-synaptic transmission of the central nervous system, resulting in a decrease in the excitability of the entire nerve cell, and increase the electrical stimulation threshold of the motor cortex. It can also inhibit the spread of epileptic foci discharge. |
| pharmacokinetics | oral absorption, tmax is 2.7~5.2h (adult),4~6h (child). Bioavailability is as high as 92%. Widely distributed, can pass through the placenta, milk secretion, Vd is 0.64~0.72L/kg, plasma protein binding rate is low. T1/2 is about 10h. Liver metabolism, renal excretion. |
| indications | for epilepsy tonic-clonic seizures (grand seizures), simple partial seizures and complex partial seizures monotherapy or combination therapy, also for the treatment of essential tremor and senile tremor. |
| adverse reactions | 1. It can produce vision changes, diplopia, nystagmus, ataxia, cognitive retardation, affective disorder, confusion, shortness of breath or disorders, hand and foot immobility or walking instability, joint contracture, dizziness and lethargy. 2. Rare sexual dysfunction, headache, loss of appetite, fatigue, nausea or vomiting. 3. Occasionally there are allergic reactions (dyspnea, eyelid swelling, wheezing or chest urgency), granulocytopenia, aplastic anemia, red blood cell dysplasia, giant cell anemia. Toxic epidermal necrosis may occur. |
| drug interaction | [1] When combined with ethanol, anesthetics, antihypertensive drugs that mainly act on the central part, other central inhibitory drugs, and magnesium sulfate for injection, it will enhance central inhibition and lead to respiratory depression. The dose needs to be adjusted. [2] Combined use of anticoagulants, adrenal cortex hormones, digoxin, doxycycline or tricyclic antidepressants, due to the induction of liver drug enzymes, the metabolism of the above drugs increases faster and the efficacy decreases. [3] When combined with MAOIs, the blood concentration increases, which can cause adverse reactions. [4] Combined use of griseofulvin can cause malabsorption of griseofulvin and reduce the efficacy. [5] It can increase the excretion of vitamin C, reduce the absorption of vitamin B12, and accelerate the metabolism of vitamin D. [6] Combined use of carbamazepine, due to enzyme induction, the metabolism of both is accelerated and the efficacy is reduced. When combined use, the blood concentration of the two drugs should be monitored, and other antiepileptic drugs should be combined. Changes in the form of seizures due to changes in metabolism, Need to adjust the dose in time; the combined use of sodium valproate slows down the clearance of metabolites, which can cause severe central inhibition. [7] The blood concentration of quetiapine can decrease, and the dose needs to be adjusted to maintain the efficacy. |
| Overdose | Overdose may cause the production of crystalline urine, which may be related to the concentration of promione in the serum exceeding 80 μg/mL and renal damage. Treatment: symptomatic and supportive treatment. |
| biological activity | Primidone (NCI-C56360) is a pyrimidine diketone anticonvulsant. |
| Target | Value |
| use | for grand epilepsy and psychomotor seizures. The anti-epileptic effect is similar to phenobarbital, but it is more selective than phenobarbital; the intensity of the effect is not as strong as phenytoin, but the combination of the two has a synergistic effect. |
| production method | add ethyl acetate to sodium ethoxide, reflux for half an hour, cool to room temperature, add diethyl ethylphenylmalonate and thiourea, add flow for 9 hours. Cold to 0 ℃, add ethanol, drip hydrochloric acid at 0-5 ℃ to pH = 3-3.5. Add zinc powder, raise the temperature to reflux, slowly add hydrochloric acid, keep the liquid with 2-3% acid content, add it, keep it for 3 hours. Filter while hot, and the filtrate recovers ethanol. Cold to 20 ℃, add water, filter, wash the filter cake to obtain promione. |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 20:52:54
Supplier List
Spot supply
Product Name: Primidone Visit Supplier Webpage Request for quotationCAS: 125-33-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Primidone Visit Supplier Webpage Request for quotationCAS: 125-33-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History